Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

C1950000

Chlorthalidone

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

Select a Size

150 MG
€133.00

€133.00

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
150 MG
€133.00

About This Item

Empirical Formula (Hill Notation):
C14H11ClN2O4S
CAS Number:
77-36-1
Molecular Weight:
338.77
MDL number:
MFCD00036257
UNSPSC Code:
41116107
PubChem Substance ID:
329774919
NACRES:
NA.24

€133.00

Please contact Customer Service for Availability
Request a Bulk Order

grade

pharmaceutical primary standard

API family

chlorthalidone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23

InChI

1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)

InChI key

JIVPVXMEBJLZRO-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Chlorthalidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

George C Roush et al.
Current hypertension reports, 15(5), 514-521 (2013-07-11)
How chlorthalidone (CTDN) reduces risk for cardiovascular events (CVEs) can be considered in light of its ability to lower blood pressure (BP) and its non-BP related, pleiotropic effects. The mechanism by which CTDN lowers BP is unclear but may include
Kimberly M Neff et al.
Cardiology in review, 18(1), 51-56 (2009-12-17)
Thiazide diuretics are a mainstay for the treatment of hypertension. Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure. This is despite several clinical trials that
Jerrica E Shuster et al.
Vascular health and risk management, 8, 381-387 (2012-06-30)
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing
James R Singer et al.
Journal of glaucoma, 24(1), 84-86 (2014-01-23)
To report a novel case of acute bilateral uveal effusions, angle closure, and acute myopia induced by administration of chlorthalidone. Case report. Bilateral shallow anterior chambers, high intraocular pressure, and a myopic shift were encountered in a patient 1 week
Sandra J Taler
Current hypertension reports, 10(4), 293-297 (2008-07-16)
For decades, diuretic therapy has been a cornerstone in treating hypertension, an approach supported by multiple randomized controlled trials demonstrating reduced morbidity and mortality from cardiovascular events. Yet controversy persists regarding the potential detrimental metabolic effects and side effects of
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service